PeruvosidePeruvoside
MedChemExpress (MCE)
HY-108016
1182-87-2
Encordin
99.32%
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Room temperature in continental US
may vary elsewhere.
Peruvoside is a potent inhibitor of Src, PI3K, JNK, STAT, and EGFR. Peruvoside induces apoptosis and autophagy and possesses a broad spectrum of anticancer activity in breast, lung, liver cancers and leukemia. Peruvoside is a broad-spectrum and potent antiviral activity against positive-sense RNA viruses. Peruvoside sensitizes Gefitinib (HY-50895)-resistant tumour cells (A549, PC9/gef and H1975) to Gefitinib.
Peruvoside (50-1000 nM, 24 h) inhibits the viability and proliferation in PC9, PC9/gef, H3255, and H1975 cell lines[1]. Peruvoside (0.005-0.5 μM, 72 h) sensitizes A549, PC9/gef and H1975 to Gefitinib when in combination with Gefitinib (0.01~0.5 μM)[1]. Peruvoside (0-100 μM, 24 h) induces cell cycle arrest and apoptosis in MCF-7, HpG2, and A549 cells[2.
Peruvoside (0.1 mg/kg for i.p
once daily for 28 days) suppresses the tumour growth in lung cancer mice model[1]. Peruvoside (0.59 mg/kg for i.p
once daily for 7 days) reduces mortality in EV-A71-infected mice model[4].
| | | |
| | | | | |
[1]. Lai Y, et al. Peruvoside is a novel Src inhibitor that suppresses NSCLC cell growth and motility by downregulating multiple Src-EGFR-related pathways. Am J Cancer Res. 2022 Jun 15
12(6):2576-2593. [Content Brief]
[2]. Reddy D, et al. Peruvoside targets apoptosis and autophagy through MAPK Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways in human cancers. Life Sci. 2020 Jan 15
241:117147. doi: 10.1016/j.lfs.2019.117147. Epub 2019 Dec 9. PMID: 31830480. [Content Brief]
[3]. Feng Q, et al. Peruvoside, a Cardiac Glycoside, Induces Primitive Myeloid Leukemia Cell Death. Molecules. 2016 Apr 22
21(4):534.
[4]. Wu KX, et al. The host-targeting compound peruvoside has a broad-spectrum antiviral activity against positive-sense RNA viruses. Acta Pharm Sin B. 2023 May
13(5):2039-2055.